United States · Funded startup

Who invested in Telesis Bio

One round we have observed, with the one investor named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$74Mraised across 1 round since 2023, from 1 source

Latest round
Round, $74MMay 2023
Investors
1
See who backed them

The rounds

  1. May 2023
    Round$74M

    Source recordedSEC filing: $28M sold, first sale Jun 2023

Founders and team

From Telesis Bio's own website and the SEC filings it signed: 10 on the team.

  • Andrea L. JacksonDirector,
  • Daniel G. GibsonExecutive Officeri
  • Eric H. EsserExecutive Officeri
  • Franklin R. WitneyChair of the Board of Directorsi
  • Robert H. CutlerExecutive Officeri
  • Todd R. NelsonExecutive Officer, Directori
  • Jim WeissmanTeam
  • Michael HodgesTeam
  • Sarah HlavinkaTeam
  • Todd KruegerTeam

On the board, as filediAnnette V. TumoloChristine A. TsingosJami A. NachtsheimPaul V. MeisterWilliam F. Snider

AdvisersGreg Herrema

Everyone who backed them

Northpond VenturesPrivate equity1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about Telesis Bio

Who invested in Telesis Bio?

Telesis Bio's investors include Northpond Ventures.

How much has Telesis Bio raised?

Telesis Bio has raised $74M across 1 round since 2023.

When did Telesis Bio last raise?

Telesis Bio's most recent round was an Undisclosed round of $74M in May 2023.

What was Telesis Bio's biggest round?

Its most recent round, $74M in May 2023, is also its largest on record.

Who backed Telesis Bio first?

Telesis Bio's first round on record, in May 2023, was backed by Northpond Ventures.

What stage is Telesis Bio at?

Telesis Bio's latest named round is an Undisclosed round, in May 2023.

Where is Telesis Bio based?

Telesis Bio is based in the United States.

Companies like Telesis Bio

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.